

FIG 4 IL-1 α induces MIP-1 β expression in JFH1-infected Huh7.5 cells. (A) Huh7.5 and JFH1-infected Huh7.5 (Huh7.5/JFH1) cells were treated with recombinant MCP-2 (10 ng/ml), recombinant MCP-3 (rMCP-3; 10 ng/ml), recombinant TSG14 (10 ng/ml), or recombinant IL-1 α (10 pg/ml) for 24 h. The level of MIP-1 β expression was analyzed by qRT-PCR as described for Fig. 1A. (B) Huh7.5 and JFH1-infected Huh7.5 (Huh7.5/JFH1) cells were treated with various amounts of recombinant IL-1 α (0, 0.1, 1.0, 10, or 100 pg/ml) for 24 h. The level of MIP-1 β expression was analyzed by qRT-PCR as described for Fig. 1A. (C) JFH1-infected Huh7.5 cells were treated with Huh7.5 CM or LX2 CM along with an isotype control (0.2 μ g/ml), anti-IL-1 α (0.2 μ g/ml), or IL-1RA (100 μ g/ml) for 24 h. The level of MIP-1 β expression was analyzed by qRT-PCR as described for Fig. 1A. (D) Huh7.5 and Huh7.5/JFH1 cells were transfected with 50 nM control siRNA (siControl) or 50 nM IRAK1 siRNA (siIRAK1). At 48 h after transfection, cells were treated with Huh7.5 CM or LX2 CM. The level of MIP-1 β expression was analyzed by qRT-PCR as described for Fig. 1A. The results are representative of three independent experiments, and the error bars represent the standard deviations of the means.

MIP-1 β induction in Huh7.5/JFH1 cells that were cultured in the presence of LX2 CM was suppressed by pretreatment of the cells with a neutralizing antibody against anti-CD81. To further address whether MIP-1 β induction by LX2 CM in Huh7.5/JFH1 cells is due to the binding of HCV E1/E2 to the receptor, JFH1-infected cells were UV irradiated and used to infect Huh7.5 cells. Huh7.5 cells infected with UV-irradiated JFH1 did not show MIP-1 β induction stimulated by LX2 CM (Fig. 6D). In addition, ectopic expression of HCV proteins in Huh7.5 cells did not respond to the LX2 CM (Fig. 6E). These results suggest that MIP-1 β expression is required for HCV infection at postentry.

DISCUSSION

HCV-specific CTLs are concentrated within the liver during chronic infection, and they may control viral replication and contribute to progressive liver disease (19). Recruitment of T cells to the liver is required for the expression of CCR5 on activated T cells (20). Intrahepatic expression of the ligands for CCR5 (RANTES, MIP-1 β , and MIP-1 α) is elevated in HCV patients, and these

chemokines have been linked to a high degree of liver inflammation (21). However, the mechanism mediating the stimulation of these cytokines is unclear. In this study, we demonstrated that cross talk between HCV-infected hepatocytes and human stellate cells (HSCs) induced inflammatory cytokines and chemokines. Importantly, uninfected hepatocytes are tolerant of HSC stimulation. Of note, HCV has no direct effect on LX2 cells with regard to MIP-1 β stimulation because MIP-1 β expression in Huh7.5/JFH1 cells was induced by treatment with CM from JFH1-treated LX2 cells as well as LX2 CM.

We identified IL-1 α as an inducer of cytokines and chemokines in HCV-infected hepatocytes. These cells are highly sensitive to IL-1 α (Fig. 4). Previous reports have indicated that the HCV core and NS3 proteins, which induced IL-1 receptor-associated kinase (IRAK) activity, triggered inflammatory cell activation through TLR-2 (22). IRAK activation by HCV infection may contribute to the induction of cytokines and chemokines by HSCs. We addressed this point and found that knockdown of IRAK1 in HCV-




FIG 6 HCV entry is required for induction of MIP-1 β expression by LX2 CM. (A) Huh7.5, JFH1-infected Huh7.5 (Huh7.5/JFH1), and JFH1-CL3B-infected Huh7.5 (Huh7.5/JFH1-CL3B) cells were treated with Huh7.5 CM or LX2 CM for 24 h. The level of MIP-1 β expression was analyzed by qRT-PCR as described for Fig. 1A. (B) Huh7.5 cells were treated with Huh7.5 CM or LX2 CM. After 24 h of treatment, cells were infected with JFH1 for 2, 4, or 6 h. The level of MIP-1 β expression was analyzed by qRT-PCR as described for Fig. 1A. (C) Huh7.5 cells were treated with Huh7.5 CM or LX2 CM in the presence of an isotype control IgG or anti-CD81 antibody (1 μ g/ml). After 24 h of treatment, the cells were infected with JFH1 in the presence of an isotype control IgG or anti-CD81 antibody (1 μ g/ml) for 2, 4, or 6 h. The level of MIP-1 β expression was analyzed by qRT-PCR as described for Fig. 1A. (D) HCV JFH1 was UV irradiated and used to infect Huh7.5 cells. At 24 h after infection, cells were treated with Huh7.5 CM or LX2 CM. The level of MIP-1 β expression was analyzed by qRT-PCR as described for Fig. 1A. (E) Huh7.5 cells expressing the indicated HCV proteins were treated with Huh7.5 CM or LX2 CM for 24 h. The levels of MIP-1 β expression were analyzed by qRT-PCR as described for Fig. 1A. The results are representative of three independent experiments, and the error bars represent the standard deviations of the means.

posttranslational modification in response to IL-1 treatment. It is possible that activation of the MAPK (33) and ERK pathways (34) by HCV infection induces phosphorylation of C/EBP β , leading to a highly sensitive IL-1 response. Further studies will be required to clarify the details of how HCV modulates increased MIP1- β production through both the C/EBP β and IL-1 receptor signaling pathways.

This study revealed that induction of inflammatory cytokines and chemokines by cross talk between HSCs and HCV-infected hepatocytes primarily involves the activation of C/EBP β -dependent gene transcription, such as transcription of the IL-6, IL-8, CXCL-1, and MIP-1 β genes (Fig. 5). A recent study demonstrated that the HCV NS5A protein induces C/EBP β expression (35). However, treatment of Huh7.5 cells that expressed NS5A with HCS

CM did not induce MIP-1 β expression significantly (Fig. 6E). We also observed only a marginal increase in MIP-1 β mRNA level by solitary expression of each HCV protein in Huh7.5 cells by addition of LX2 CM (Fig. 6E).

Moreover, previous reports have suggested that ER stress, which is induced by HCV infection, leads to the generation of mature sterol regulatory element-binding protein 1 (SREBP-1) (36, 37) and that the mature SREBP-1c can bind to the C/EBP β promoter (36, 38), leading to induction of C/EBP β . Additionally, SREBP-1c promoter activity was upregulated in core-transgenic mice in a PA28 γ -dependent manner (39). Indeed, we observed that endoplasmic reticulum (ER) stress-related genes and SREBP-1c expression were enhanced by HCV infection. However, induction of SREBP-1c is not involved in this process because HCV-infected cells that had SREBP-1c knocked down could still respond to HSC CM (data not shown).

Chronic inflammation is triggered by many events that also can increase the risk of developing cancer. For example, *Helicobacter pylori* is associated with gastric cancer, and inflammatory bowel disease is associated with colon cancer. In particular, IL-6 is one of the clinical targets for cancer-related inflammation (2). The level of IL-6 expression correlates with a rapid progression from hepatitis to hepatocellular carcinomas (40). The Ras and Jak/Stat pathway, which is downstream of the IL-6 receptor, is activated in hepatocellular carcinomas that have a poor prognosis (41). Additionally, IL-8 is a proinflammatory cytokine that specifically attracts and activates human neutrophils. In HCV patients, pegylated IFN- α -2a (PEG-IFN- α -2a) and ribavirin therapy decreased the neutrophil count in virologic responders compared to nonresponders (42). Enhancement of expression of these cytokines as well as MIP-1 β , described here, suggests that the cross talk between HCV-infected hepatocytes and HSCs polarizes the cytokine profile toward a Th2-type immune response.

In conclusion, we have demonstrated that the cross talk between HSCs and HCV-infected hepatocytes results in the induction of inflammatory cytokines and chemokines, which promote the migration of CCR5-expressing cells in *in vitro* experiments. These results suggest that the induction of inflammatory cytokines and chemokines by HCV infection may recruit inflammatory cells such as cytotoxic T lymphocytes (CTL) and neutrophils to the liver, which induces liver cell injury leading to chronic hepatitis.

ACKNOWLEDGMENTS

We are grateful to H. Hoshino at Gunma University, C. Rice at The Rockefeller University, S. Friedman at Mount Sinai School of Medicine, and T. Wakita at the National Institute of Infectious Diseases for their contributions of research materials and to H. Yamamoto and R. Shiina for their technical assistance.

This work was partly supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), by the MEXT-Supported Program for the Strategic Research Foundation at Private Universities, and by grants-in-aid for research on hepatitis from the Ministry of Health, Labor, and Welfare of Japan.

REFERENCES

- Bartosch B, Thimme R, Blum HE, Zoulim F. 2009. Hepatitis C virus-induced hepatocarcinogenesis. *J. Hepatol.* 51:810–820.
- Bowen DG, Walker CM. 2005. Adaptive immune responses in acute and chronic hepatitis C virus infection. *Nature* 436:946–952.
- Liaw YF, Lee CS, Tsai SL, Liaw BW, Chen TC, Sheen IS, Chu CM. 1995. T-cell-mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. *Hepatology* 22:1368–1373.
- Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. 1999. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. *J. Immunol.* 163:6236–6243.
- Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, Marinos G, Lloyd AR. 2003. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. *J. Leukoc. Biol.* 74:360–369.
- Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. 1996. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. *Hepatology* 24:759–765.
- Basu A, Meyer K, Lai KK, Saito K, Di Bisceglie AM, Grosso LE, Ray RB, Ray R. 2006. Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. *Virology* 349:347–358.
- Li K, Li NL, Wei D, Pfeffer SR, Fan M, Pfeffer LM. 2012. Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. *Hepatology* 55:666–675.
- Wagoner J, Austin M, Green J, Imaizumi T, Casola A, Brasier A, Khabar KS, Wakita T, Gale M, Jr, Polyak SJ. 2007. Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during hepatitis C virus infection. *J. Virol.* 81:309–318.
- Yu GY, He G, Li CY, Tang M, Grivennikov S, Tsai WT, Wu MS, Hsu CW, Tsai Y, Wang LH, Karin M. 2012. Hepatic expression of HCV RNA-dependent RNA polymerase triggers innate immune signaling and cytokine production. *Mol. Cell* 48:313–321.
- Friedman SL. 2008. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. *Physiol. Rev.* 88:125–172.
- Friedman SL. 2008. Mechanisms of hepatic fibrogenesis. *Gastroenterology* 134:1655–1669.
- Hernandez-Gea V, Friedman SL. 2011. Pathogenesis of liver fibrosis. *Annu. Rev. Pathol.* 6:425–456.
- Coulouarn C, Corlu A, Glaise D, Guénon I, Thorgerisson SS, Clément B. 2012. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. *Cancer Res.* 72:2533–2542.
- Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, Mukherjee P, Friedman SL, Eng FJ. 2005. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. *Gut* 54:142–151.
- Murakami K, Abe T, Miyazawa M, Yamaguchi M, Masuda T, Matsuura T, Nagamori S, Takeuchi K, Abe K, Kyogoku M. 1995. Establishment of a new human cell line, LI90, exhibiting characteristics of hepatic Ito (fat-storing) cells. *Lab. Invest.* 72:731–739.
- Zhang Z, Bryan JL, DeLassus E, Chang LW, Liao W, Sandell LJ. 2010. CCAAT/enhancer-binding protein β and NF- κ B mediate high level expression of chemokine genes CCL3 and CCL4 by human chondrocytes in response to IL-1 β . *J. Biol. Chem.* 285:33092–33103.
- Masaki T, Suzuki R, Murakami K, Aizaki H, Ishii K, Murayama A, Date T, Matsuura Y, Miyamura T, Wakita T, Suzuki T. 2008. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. *J. Virol.* 82:7964–7976.
- Freeman AJ, Pan Y, Harvey CE, Post JJ, Law MG, White PA, Rawlinson WD, Lloyd AR, Marinos G, Ffrench RA. 2003. The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection. *J. Hepatol.* 38:349–356.
- Zeremski M, Petrovic LM, Talal AH. 2007. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. *J. Viral Hepat.* 14:675–687.
- Wald O, Weiss ID, Galun E, Peled A. 2007. Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics. *Cytokine* 39:50–62.
- Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G. 2004. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. *Gastroenterology* 127:1513–1524.
- Abe T, Kaname Y, Hamamoto I, Tsuda Y, Wen X, Tagawa S, Moriishi

- K, Takeuchi O, Kawai T, Kanto T, Hayashi N, Akira S, Matsuura Y. 2007. Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. *J. Virol.* 81:8953–8966.
24. Kasprzak A, Zabel M, Biczysko W, Wysocki J, Adamek A, Spachacz R, Surdyk-Zasada J. 2004. Expression of cytokines (TNF-alpha, IL-1alpha, and IL-2) in chronic hepatitis C: comparative hybridocytochemical and immunocytochemical study in children and adult patients. *J. Histochem. Cytochem.* 52:29–38.
 25. Winwood PJ, Arthur MJ. 1993. Kupffer cells: their activation and role in animal models of liver injury and human liver disease. *Semin. Liver Dis.* 13:50–59.
 26. Wilkinson J, Radkowski M, Eschbacher JM, Laskus T. 2010. Activation of brain macrophages/microglia cells in hepatitis C infection. *Gut* 59: 1394–1400.
 27. Harrison JR, Kelly PL, Pilbeam CC. 2000. Involvement of CCAAT enhancer binding protein transcription factors in the regulation of prostaglandin G/H synthase 2 expression by interleukin-1 in osteoblastic MC3T3-E1 cells. *J. Bone Miner. Res.* 15:1138–1146.
 28. Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, Nakajima T, Hirano T, Kishimoto T. 1990. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. *EMBO. J.* 9:1897–1906.
 29. Nakajima T, Kinoshita S, Sasagawa T, Sasaki K, Naruto M, Kishimoto T, Akira S. 1993. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. *Proc. Natl. Acad. Sci. U. S. A.* 90:2207–2211.
 30. Zhu S, Yoon K, Sterneck E, Johnson PF, Smart RC. 2002. CCAAT/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. *Proc. Natl. Acad. Sci. U. S. A.* 99:207–212.
 31. Wegner M, Cao Z, Rosenfeld MG. 1992. Calcium-regulated phosphorylation within the leucine zipper of C/EBP beta. *Science* 256:370–373.
 32. Giltiay NV, Karakashian AA, Alimov AP, Ligthle S, Nikolova-Karakashian MN. 2005. Ceramide- and ERK-dependent pathway for the activation of CCAAT/enhancer binding protein by interleukin-1beta in hepatocytes. *J. Lipid Res.* 46:2497–2505.
 33. George A, Panda S, Kudmulwar D, Chhatbar SP, Nayak SC, Krishnan HH. 2012. Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F (eIF4F) complex and up-regulates host translation initiation machinery through eIF4E-binding protein 1 inactivation. *J. Biol. Chem.* 287:5042–5058.
 34. Zhao LJ, Wang L, Ren H, Cao J, Li L, Ke JS, Qi ZT. 2005. Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptors. *Exp. Cell Res.* 305: 23–32.
 35. Qadri I, Choudhury M, Rahman SM, Knotts TA, Janssen RC, Schaack J, Iwahashi M, Puljak L, Simon FR, Kilic G, Fitz JG, Friedman JE. 2012. Increased phosphoenolpyruvate carboxykinase gene expression and steatosis during hepatitis C virus subgenome replication: role of nonstructural component 5A and CCAAT/enhancer-binding protein beta. *J. Biol. Chem.* 287:37340–37351.
 36. Lei X, Zhang S, Barbour SE, Bohrer A, Ford EL, Koizumi A, Papa FR, Ramanaidham S. 2010. Spontaneous development of endoplasmic reticulum stress that can lead to diabetes mellitus is associated with higher calcium-independent phospholipase A2 expression: a role for regulation by SREBP-1. *J. Biol. Chem.* 285:6693–6705.
 37. Joyce MA, Walters KA, Lamb SE, Yeh MM, Zhu LF, Kneteman N, Doyle JS, Katze MG, Tyrrell DL. 2009. HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice. *PLoS Pathog.* 5:e1000291. doi:10.1371/journal.ppat.1000291.
 38. Le Lay S, Lefrère I, Trautwein C, Dugail I, Krief S. 2002. Insulin and sterol-regulatory element-binding protein-1c (SREBP-1C) regulation of gene expression in 3T3-L1 adipocytes. Identification of CCAAT/enhancer-binding protein beta as an SREBP-1C target. *J. Biol. Chem.* 277: 35625–35634.
 39. Moriishi K, Mochizuki R, Moriya K, Miyamoto H, Mori Y, Abe T, Murata S, Tanaka K, Miyamura T, Suzuki T, Koike K, Matsuura Y. 2007. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. *Proc. Natl. Acad. Sci. U. S. A.* 104:1661–1666.
 40. Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, Ng EK, Chan FK, Sung JJ, Chan HL. 2009. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. *Int. J. Cancer* 124:2766–2770.
 41. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS. 2006. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. *Gastroenterology* 130:1117–1128.
 42. Chung RT, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Di Bisceglie AM. 2010. Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. *Hepatology* 52:1906–1914.

ARTICLE

Received 24 Sep 2012 | Accepted 10 Apr 2013 | Published 14 May 2013

DOI: 10.1038/ncomms2857

Toll-like receptor 3 recognizes incomplete stem structures in single-stranded viral RNA

Megumi Tatematsu¹, Fumiko Nishikawa², Tsukasa Seya¹ & Misako Matsumoto¹

Endosomal Toll-like receptor 3 (TLR3) serves as a sensor of viral infection and sterile tissue necrosis. Although TLR3 recognizes double-stranded RNA, little is known about structural features of virus- or host-derived RNAs that activate TLR3 in infection/inflammatory states. Here we demonstrate that poliovirus-derived single-stranded RNA segments harbouring stem structures with bulge/internal loops are potent TLR3 agonists. Functional poliovirus-RNAs are resistant to degradation and efficiently induce interferon- α/β and proinflammatory cytokines in human and mouse cells in a TLR3-dependent manner. The N- and C-terminal double-stranded RNA-binding sites of TLR3 are required for poliovirus-RNA-mediated TLR3 activation. Like polyriboinosinic:polyribocytidylic acid, a synthetic double-stranded RNA, these RNAs are internalized into cells via raftlin-mediated endocytosis and colocalized with TLR3. Raftlin-associated RNA uptake machinery and the TLR3 RNA-sensing system appear to recognize an appropriate topology of multiple RNA duplexes in poliovirus-RNAs. Hence, TLR3 is a sensor of extracellular viral/host RNA with stable stem structures derived from infection or inflammation-damaged cells.

¹Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan.

²Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba 305-8566, Japan. Correspondence and requests for materials should be addressed to M.M. (email: matumoto@pop.med.hokudai.ac.jp).

Type I interferon (IFN) production is crucial for controlling virus infections^{1,2}. Toll-like receptors (TLRs) 3, 7, 8 and 9 and RIG-I-like receptors detect viral nucleic acids in the endosomes and cytoplasm, respectively, and induce cytokine production, including type I IFNs (IFN- α and IFN- β), via distinct adaptor proteins³. TLR3 recognizes double-stranded RNA (dsRNA), a viral replication intermediate that is produced by positive-strand RNA viruses and DNA viruses, and signals to produce IFN- β and proinflammatory cytokines through the Toll-interleukin-1 (IL-1) receptor domain-containing adaptor molecule-1 (TICAM-1, also known as TRIF)^{4–8}. TLR3 is expressed at high levels in myeloid dendritic cells (DCs), especially in professional antigen-presenting DCs, such as mouse splenic CD8 α^+ DCs and human CD141 $^+$ DCs, and localizes to the early endosome^{9–11}. Although macrophages, fibroblasts and epithelial cells also express TLR3 on the cell surface as well as the endosomal membrane, TLR3-mediated signalling initiates from the endosomal compartment¹². Thus, TLR3 activation depends on the uptake of extracellular virus-derived RNA molecules.

Studies using TLR3-deficient mice demonstrated that TLR3 mediates a protective response against positive-strand RNA virus infection, including coxsackie virus group B serotype 3, encephalomyocarditis virus and poliovirus (PV), all of which belong to the *Picornaviridae* family^{13–16}. TLR3- or TICAM-1-deficient human PV receptor (PVR)-transgenic mice were more susceptible than normal PVR-transgenic mice to intraperitoneal or intravenous inoculation with a low titre of PV^{15,16}. TLR3-dependent type I IFN production by splenic CD11c $^+$ DCs and macrophages was essential for the protection of PVR-transgenic mice against PV infection. In addition to mouse studies, genetic studies in the patients with herpes simplex encephalitis demonstrated that the TLR3-TICAM-1 pathway is involved in the protection against herpes simplex virus-1 encephalitis in children^{17–19}. Collectively, these findings indicate that TLR3 has an important role in antiviral responses in both humans and mice. However, several studies have also demonstrated that TLR3-mediated signalling exacerbates RNA virus infection including West Nile virus (positive-strand RNA virus), influenza virus and phlebovirus (negative-strand RNA viruses)^{20–22}. TLR3-dependent inflammatory cytokine and chemokine productions have an impact on virus-induced pathology and host survival, and, remarkably, RNA from necrotic cells or host mRNA are also recognized by TLR3^{23,24}. However, RNA species detected by TLR3 have not been analysed and little is known about the essential structural elements of virus- or host-derived RNAs capable of activating TLR3 in an infection/inflammatory state.

In the current study, we analysed the RNA structure recognized by TLR3 using *in vitro*-transcribed RNAs derived from PV. We found that, in addition to dsRNA, PV-derived structured RNAs harbouring ds regions with bulges and internal loops are potent TLR3 ligands. The PV-RNAs activated endosomal TLR3 in mouse and human cells, leading to the production of IFN- α/β and proinflammatory cytokines.

Results

Identification of RNA structures recognized by TLR3. To examine whether viral RNA activates TLR3 extracellularly, mouse splenic DCs from wild-type (WT) or TLR3-deficient mice were stimulated with total RNA isolated from PV-infected or uninfected Vero cells, or a synthetic viral dsRNA analogue, polyribonucleic:polyribocytidylic acid (poly(I:C)), in FCS-free medium. Poly(I:C) induced type I IFN production by mouse splenic DCs in a TLR3-independent manner (Fig. 1a). The results reflect a current notion that cytosolic RNA helicase, melanoma

differentiation-associated gene 5 (MDA5), in addition to endosomal TLR3, senses poly(I:C) to induce type I IFNs in mouse DCs²⁵. However, this is not the case in RNA from PV-infected cells, which induces type I IFNs and proinflammatory cytokines in splenic DCs largely through their TLR3 (Fig. 1a and Supplementary Fig. S1). Notably, RNA from PV-uninfected cells had no potential for IFN/cytokine induction (Fig. 1a and Supplementary Fig. S1). Given that PV infection leads to a rapid inhibition of host-cell RNA synthesis²⁶, the main RNA species in PV-infected Vero cells were approximately 8,000-nucleotide (nt) RNA corresponding to the PV genome and its replicative form, which were segmented into approximately 1,000–2,000-nt RNAs in the FCS-free culture medium (Fig. 1b). The ~8,000-nt PV-RNAs were degraded by treatment with single-stranded RNA (ssRNA)- and dsRNA-specific RNase, suggesting the existence of ss and ds forms of PV-derived RNAs in PV-infected cells (Supplementary Fig. S2).

A functional screening for PV-derived ssRNA and dsRNA was performed using an IFN- β promoter reporter assay to determine the RNA structure recognized by TLR3. Approximately 540–920 nts contiguous sense (PV1–10) or complementary (cPV1–10) RNAs and their dsRNA forms (dsPV1–10) were transcribed *in vitro* using PV-cDNA as a template (Fig. 1c and Supplementary Table S1), and their TLR3-activating ability was assessed. HEK293 cells transfected with the TLR3-expression vector or empty vector, together with the IFN- β promoter reporter plasmid, were stimulated with PV-RNAs in FCS-free or FCS-containing media. All PV-derived dsRNAs induced TLR3-dependent IFN- β promoter activation similar to poly(I:C) (Fig. 1d, left panel). Interestingly, several PV-ssRNAs, either sense or complementary RNA, also activated the IFN- β promoter through TLR3 in FCS-free medium (Fig. 1d, centre and right panels). We further examined the effect of FCS on the IFN- β -inducing abilities of PV-RNAs using PV5. PV5 retained TLR3-activating ability, even in the FCS-containing medium (Fig. 1e).

To explore the relationship between TLR3-activating capacity and the degradability of PV-RNAs, PV-RNAs were incubated in FCS(-) or FCS(+) medium for 30 min at 37°C and then subjected to agarose gel electrophoresis. Non-functional PV-RNAs were readily degraded in the FCS(-) or FCS(+) medium, whereas functional RNAs, including high-potential PV5 and cPV5 and low-potential PV6, were stable before and after incubation in the FCS(+) medium (Fig. 2a). Correspondingly, dose-dependent TLR3 activation was observed with PV5 and PV6 but not with others including cPV1 (Fig. 2b). Notably, these PV-RNAs stimulated the cytosolic RNA sensors when transfected into cells (Supplementary Fig. S3a). TLR3-mediated IFN- β promoter activation was also observed with PV5- or cPV5-containing long-size PV-RNAs, although the activity was less than that of PV5 (Supplementary Fig. S3b and Supplementary Table S1). In addition, segmentation of PV5 into three ~200-nt RNAs (PV5 a, b and c) destroyed the activity of intact PV5, despite the fact that these RNA segments were resistant to degradation (Supplementary Fig. S3c and Supplementary Table S1). These results suggested that an appropriate length of PV-RNAs with a stable structure activate endosomal TLR3, inducing IFN- β promoter activation.

PV-RNAs induce IFN- β production by human fibroblasts. We next examined whether PV-RNAs induced IFN- β production from human fibroblasts and epithelial cells that endogenously expressed TLR3. MRC5 cells were stimulated with cPV1, PV5, PV6 or dsPV5 extracellularly, and IFN- β mRNA was assessed using quantitative PCR (qPCR). PV5 and PV6 induced IFN- β mRNA expression in MRC5 cells similar to dsPV5 stimulation




Figure 1 | Extracellular PV-RNAs induce TLR3-mediated type I IFN production. (a) Mouse splenic CD11c⁺ DCs from WT or TLR3^{-/-} mice (1 × 10⁶ per ml) were stimulated with medium alone (-), poly(I:C), total RNA from PV-infected Vero cells or total RNA from uninfected Vero cells (25, 100 μg ml⁻¹) for 24 h in FCS(-) AIM-V medium. RNAs were pre-treated with polymyxin B (5 μg ml⁻¹) for 1 h before addition. IFN- α / β levels in culture supernatants were measured using ELISA. Representative data from three independent experiments are shown (mean ± s.d.). (b) The RNA extracted from PV-infected or uninfected Vero cells was incubated in FCS(-) AIM-V medium for 30 min and then electrophoresed on a 1% agarose gel. The PV-RNAs were segmented into approximately 1,000–2,000-nt RNAs in FCS-free medium (right panel, square bracket). (c) Constructs of *in vitro*-transcribed PV-RNAs. Diagram of PV genome is shown (Top). Coding regions for viral capsid proteins (P1) and noncapsid proteins (P2 and P3) are indicated. Positions of the sense RNAs (PV1–10) and the complementary RNAs (cPV1–10) corresponding to the PV genome are shown as arrows. Each starting and ending position and length are described in Supplementary Table S1. (d) PV-RNA-induced TLR3-mediated IFN- β promoter activation. HEK293 cells were transfected with an empty vector (-) or expression plasmid for TLR3, together with the IFN- β promoter reporter and phRL-TK. Twenty-four hours after transfection, culture media was removed and 10 μg ml⁻¹ poly(I:C), PV-derived dsRNAs, dsPV1–dsPV10 (left panel), sense RNAs, PV1–PV10 (middle panel) or complementary RNAs, cPV1–cPV10 (right panel), were added with FCS-free medium. Luciferase activity was measured 6 h after stimulation and shown as mean fold index induction compared with non-stimulated cells. Representative data from three independent experiments are shown (mean ± s.d.). (e) Effect of FCS on the PV5-induced TLR3-mediated IFN- β promoter activation. Cells were stimulated with increasing amounts of poly(I:C) or PV5 (2.5, 10 or 25 μg ml⁻¹) in the condition of FCS-free or -containing medium.

(Fig. 2c). mRNA encoding the proinflammatory cytokines, IL-6 and TNF- α , were also induced by PV5, PV6 or dsPV5 (Fig. 2d). Similarly, HeLa cells greatly increased IFN- β mRNA expression in response to PV5, PV6 or dsPV5 (Fig. 2d). In contrast, cPV1 did not induce any cytokine mRNA transcription from MRC5 and HeLa cells.




Figure 2 | PV-ssRNA-induced TLR3 activation is correlated with the degradability of RNAs. (a) PV-RNAs were incubated in cell-free FCS-free or -containing medium at 37 °C. Non-treated RNA or RNA incubated for 30 min were loaded onto a 2% agarose gel. (b) HEK293 cells transiently expressing TLR3 were stimulated with increasing amounts of poly(I:C), cPV1, PV5 or PV6 ($2.5, 10$ or $25 \mu\text{g ml}^{-1}$) for 6 h. HEK293 cells transfected with empty vector were stimulated with $25 \mu\text{g ml}^{-1}$ poly(I:C) or indicated PV-RNA. IFN- β promoter activation is shown as mean fold index induction compared with non-stimulated cells. Representative data from three independent experiments are shown. (c,d) IFN- β mRNA expression induced by PV-RNAs in human cells expressing TLR3. MRC5 cells (c) or HeLa cells (d) in FCS(-) AIM-V medium were stimulated with $20 \mu\text{g ml}^{-1}$ poly(I:C) or PV-derived RNAs for 3 h. Total RNA was extracted and quantitative PCR was performed using primers for the respective genes. Expression of each gene was normalized to glyceraldehyde 3-phosphate dehydrogenase mRNA expression. Data are shown as the mean \pm s.d. Representative data from three independent experiments are shown.

TLR3 recognizes PV-RNA through the dsRNA-binding sites. Biochemical studies using *in vitro*-transcribed dsRNAs have shown that relatively long stretches of dsRNA (> 90 bp in length) are required for TLR3-mediated IFN- β promoter activation in HEK293/TLR3 cells and cytokine production from mouse myeloid DCs^{1,27}. To determine the structural features of TLR3-activating or non-activating RNAs, the secondary structure of PV-RNAs was predicted using the mfold WebServer program, which calculates the minimum free-energy secondary structure²⁸. Each PV-RNA contains ds (< 11 bp in length) and ss regions, and, intriguingly,

the percentages of stem/loop structure were almost the same in each PV-RNA (Fig. 3a). However, the secondary structure models of cPV1, PV5 and PV6 have clearly showed that cPV1 contains multiple branched stems and large loop structures that may be targeted by RNases, whereas functional PV5 and PV6 possess tandemly arranged ds regions, which were segmented with bulge or internal loops. Thus, RNAs that we prepared are not a typical ds structure of the TLR3 ligand. The topology of multiple dsRNA regions and the overall secondary and tertiary structures of PV-RNAs appear to influence the stability and TLR3-activating ability.




Figure 3 | Both N- and C-terminal dsRNA-binding sites of TLR3 are required for PV-RNA-induced TLR3 activation. (a) Secondary structure of PV-RNAs (cPV1, PV5 and PV6) predicted by the mfold software. Thick lines indicate dsRNA regions (1–11 bp). The starting and ending positions of ds regions are shown with the nt number. A total number of base pair and the number of nts involved in base pairing in cPV1, PV5 and PV6 are described under the secondary-structure model. (b) Binding affinity of PV-RNAs to TLR3 ECD under different pH conditions. ³²P-labelled PV-RNAs (cPV1 and PV5) were mixed with varying concentrations of hTLR3 ECD protein and passed through a nitrocellulose filter. After washing, bound radioactivity was measured, and binding activities were calculated as a percentage of input RNA before filtration. The apparent dissociation constant (K_d) values calculated for cPV1 and PV5 were 39 ± 16 and 10 ± 3 nM (pH 5.0), and 31 ± 13 and 7 ± 3 nM (pH 6.0), respectively. (c) HEK293 cells were transfected with an empty vector or expression plasmid for WT TLR3 or each TLR3 mutant (H39A, H39E, H60A, H60E and H539A), together with the IFN- β promoter reporter plasmid and phRL-TK. Twenty-four hours post transfection, cells were stimulated with 10 μ g ml⁻¹ poly(I:C) or PV5 in FCS-free medium. Luciferase activity was measured 6 h after stimulation. Representative data from three independent experiments are shown.

We then tested the binding ability of intact PV5 and cPV1 to the recombinant TLR3 ectodomain (ECD) protein under the various pH conditions using a filter binding assay²⁹. The ability of PV5 to bind TLR3 was higher than cPV1 at low concentrations of TLR3 ECD in an acidic environment (pH 5.0 and 6.0) (Fig. 3b). Even in a neutral pH (7.0), PV5 weakly bound to TLR3 ECD,

whereas cPV1 remained unbound (Fig. 3b). The binding of PV-RNAs to TLR3 ECD was specific because unlabelled PV5 inhibited the ^{32}P -labelled PV5 binding dose-dependently. In addition, dsDNA (200 bp in length) hardly bound to TLR3 ECD under any pH condition (Supplementary Fig. S4).

TLR3 ECD is composed of 23 leucine-rich repeats (LRRs) and the N- and C-terminal flanking regions³⁰. Structural analysis of mouse TLR3 ECD–dsRNA complex revealed that TLR3 ECD dimerized on 46-bp dsRNA³¹. dsRNA interacted with both an N- and C-terminal-binding site on the glycan-free surface of each TLR3 ECD, which are on opposite sides of the dsRNA. The point mutation analyses of human/mouse TLR3 demonstrated that H539 and N541 located in LRR20, H39 in LRR-NT and H60 in LRR1 form the C- and N-terminal-binding site, and are essential for dsRNA-induced TLR3-mediated signalling^{29,32}. We therefore investigated whether PV5, like dsRNA, activates TLR3 through interaction with the N- and C-terminal-binding sites of TLR3. When TLR3 mutants, in which H39, H60 or H539 was substituted with Ala or Glu, were expressed in HEK293 cells, PV5 failed to induce IFN- β promoter activation, similar to poly(I:C) (Fig. 3c). Thus, PV5 appears to interact with the N- and C-terminal dsRNA-binding sites of TLR3 and oligomerize the receptor, leading to the activation of downstream signalling molecules. However, we cannot rule out the possibility that amino acids of the TLR3 ECD, irrelevant to the direct dsRNA binding, participate in the interaction with PV-RNAs.

PV5 is internalized and colocalizes with endosomal TLR3.

TLR3 activation by poly(I:C) requires clathrin-mediated internalization of extracellular poly(I:C)³³. In human myeloid DCs and epithelial cells such as HeLa cells, the cytoplasmic raft protein, raflin, induces poly(I:C) uptake through interaction with clathrin–AP-2 complex^{34,35}. To understand how extracellular PV-RNAs activate endosomal TLR3, we examined the requirement of raflin in PV-RNA-induced TLR3 activation by gene silencing of raflin with small interfering RNA (siRNA). PV-ssRNA or -dsRNA-induced IFN- β promoter activation was greatly decreased when raflin was knocked down in HEK293 cells, similar to what was observed with poly(I:C) stimulation (Fig. 4a). Furthermore, raflin-knockdown HeLa cells were also impaired in their ability to induce the expression of IFN- β mRNA in response to PV5 (Fig. 4b). Again, TICAM-1 was essential for PV-RNA-induced signalling (Fig. 4a).

Immunofluorescent analyses demonstrated that surface-bound Cy3-labelled PV5 was internalized within a 5-min incubation at 37°C. PV5 colocalized with TLR3 and the early endosome marker, EEA1, after 15 min, and this was sustained for up to 60 min (Fig. 4c). In contrast, co-localization of Cy3-PV5 with LAMP1, a late endosome/lysosome marker, was observed after incubation for 30 min (Fig. 4c). The internalization of PV5 was similar to that of poly(I:C)³⁵. Indeed, PV5 activity was inhibited by the pre-treatment of cells with B-type CpG oligodeoxynucleotide (ODN), which shares an uptake receptor with poly(I:C) (Supplementary Fig. S5). Taken together, these results strongly suggest that functional PV-RNAs use the poly(I:C)/ODN-uptake receptor for raflin-mediated endocytosis and that long-term retention of PV5 in the early endosome allows TLR3 to oligomerize for IFN- β production in human cells.

PV-RNAs induce TLR3-dependent IFN production by mouse DCs. To show the TLR3 dependency in PV-RNA-induced cellular responses, mouse macrophages and DCs from WT or TLR3-deficient mice were used for cytokine assay. When bone marrow-derived macrophages from WT mice were stimulated

with cPV1, PV5, PV6 or dsPV5 in the FCS-containing medium, they produced IFN- β in response to PV5, PV6 or dsPV5 (Supplementary Fig. S6). Similarly, splenic CD11c⁺ DCs produced significant amounts of IFN- α/β , TNF- α and IL-6 in response to PV5, PV6 or dsPV5 in the FCS-containing medium (Fig. 5a). The activity of PV-RNAs were augmented in FCS-free medium (Supplementary Fig. S7). Unlike human fibroblasts and epithelial cells, mouse CD11c⁺ DCs produced cytokines in response to cPV1 with or without FCS in the media, although the levels were relatively low compared with those induced by exposure to PV5, PV6 or dsPV5. Notably, PV-RNA-induced cytokine production was absent from TLR3-deficient DCs (Fig. 5a). Remarkably, cPV1 induced substantial production of proinflammatory cytokines in FCS-free medium by mouse splenic CD8 α ⁺ DCs, expressing a high level of TLR3 in a TLR3-dependent manner, similar to cells cultured with PV5, PV6 or dsPV5 (Supplementary Fig. S8). One possible interpretation of these results is that intact cPV1 possesses TLR3-activating ability and that CD11c⁺ or CD8 α ⁺ DCs promptly take up intact cPV1 before being degraded in FCS-free or -containing medium and deliver it to the endosomal compartment where TLR3 resides. Indeed, intact cPV1 bound to the TLR3 ECD under acidic conditions, though with lower affinity than PV5 (Fig. 3b). When PV5 was pre-treated with RNaseIII, a dsRNA-specific RNase, cytokine production by splenic CD11c⁺ DCs was abrogated, indicating that RNA duplex is required for PV5-induced TLR3 activation (Fig. 5b).

The estimated secondary-structure model of PV5. To clarify the secondary structure of PV5, we performed the partial digestion of PV5 using MazF at room temperature. MazF is an ACA-specific endoribonuclease that specifically cleaves ssRNA regions at the 5'-end of the ACA sequence, but not dsRNA regions³⁶. Cleavage occurs at the 5' end of the first A residue in an ACA sequence, which produces 2',3'-cyclic phosphate and the other 5' OH group³⁷. There are 12 ACA sites in PV5. Therefore, to estimate the size of cleaved fragments, PV5-deletion mutants were also digested with MazF (Fig. 6a). Comparison of the cleaved fragments with the mutant RNAs clearly demonstrated that the 124 ACA site in PV5, which was expected to be a dsRNA region, was resistant to cleavage (Fig. 6b). At approximately the 40-mer RNA position, two fragments were detected in PV5(456)/MazF and PV5/MazF. The slow-migration band intensity increased in a time-dependent manner and the fast-migration band intensity gradually decreased. This indicated that the former may be the final digested fragment and the latter was at an intermediate stage of digestion. This was confirmed by additional digestion analyses (Supplementary Fig. S9). We compared our data with several secondary-structure models (RNAfold, mfold and centroidfold) of PV5 and determined that the mfold secondary-structure model was most fitted among them (Fig. 6b and Supplementary Fig. S10).

The core RNA structure required for TLR3 activation. Based on the mfold model, we attempted to identify the core RNA structure required for TLR3 activation in PV5. PV5-derived RNAs partly having PV5 secondary structure (PV5-D1–PV5-D5) were made by *in vitro* transcription (Fig. 7a), and their stability and TLR3-activating ability were assessed. PV5-D1, D3 and D5 were resistant to degradation, and extracellularly activate TLR3 similar to PV5, leading to IFN- β promoter activation in HEK293 cells and cytokine production in mouse splenic DCs or bone marrow-derived macrophages (Fig. 7b–d). In contrast, PV5-D2 and -D4, which were resistant to degradation in FCS-free medium but were readily degraded in FCS-containing medium,




Figure 4 | Raftlin-mediated endocytosis is essential for PV-RNA-induced IFN- β production by human cells. (a) Left panels: HEK293 cells were transfected with control, raftlin or TICAM-1 siRNAs (20 pmol), together with the expression vector for human TLR3 and the IFN- β reporter plasmid. Forty-eight hours after transfection, cells were washed and stimulated with $20 \mu\text{g ml}^{-1}$ poly(I:C) or PV-RNAs. After 6 h, luciferase reporter activity was measured and expressed as the fold induction relative to the activity of unstimulated cells. Representative data from three independent experiments are shown (mean \pm s.d.). Student's *t*-test was used for statistical analysis. * $P < 0.05$ and ** $P < 0.01$. Right panels: Knockdown of raftlin or TICAM-1 was confirmed using western blotting. (b) HeLa cells were transfected with the control or raftlin siRNAs. Forty-eight hours after transfection, cells were washed and stimulated with $20 \mu\text{g ml}^{-1}$ PV5 for 3 h. Total RNA was extracted, and quantitative PCR was performed using primers for the IFN- β and raftlin genes. Expression of genes was normalized to glyceraldehyde 3-phosphate dehydrogenase mRNA expression. Data are shown as the mean \pm s.d. Representative data from three independent experiments are shown. * $P < 0.05$. (c) HeLa cells were incubated with $15 \mu\text{g ml}^{-1}$ Cy3-PV5 for 30 min at 4 °C. After washing, cells were incubated for up to 60 min at 37 °C. At timed intervals, cells were fixed and permeabilized. After staining with anti-TLR3 mAb and anti-EEA1 pAb (upper panels) or anti-LAMP1 mAb (lower panels), cells were incubated with an Alexa Fluor-488- or -633-conjugated secondary Ab and then analysed using confocal microscopy. Red, Cy3-PV5; green, TLR3 or LAMP1; blue, EEA1; light blue, nuclei with 4',6-diamidino-2-phenylindole; white, merged PV5 with TLR3 and EEA1; and yellow, merged PV5 with LAMP1. Scale bar, 10 μm . Co-localization between PV5 and TLR3, EEA1 or LAMP1 was analysed by counting the merged PV5 spots with each molecule in 70 PV5-internalizing cells. The data are shown as % of merged PV5 with EEA1, LAMP1 or TLR3 at indicated time points.




Figure 5 | Mouse splenic DCs produce type I IFN and cytokines in response to PV-RNAs in a TLR3-dependent manner. (a) Splenic CD11c⁺ DCs (1×10^6 per ml) isolated from TLR3^{-/-} or WT mice were stimulated with $20 \mu\text{g ml}^{-1}$ poly(I:C) or PV-derived RNAs in FCS-containing medium. Twenty-four hours after stimulation, culture supernatants were collected, and IFN- α/β in the supernatants was quantified using ELISA. TNF- α and IL-6 levels were measured using CBA. Representative data from three independent experiments are shown (mean \pm s.d.). (b) Poly(I:C) and PV5 ($20 \mu\text{g ml}^{-1}$) were pre-treated with RNaseIII for 30 min at 37°C or left untreated before adding to CD11⁺ splenic DCs (1×10^6 per ml) isolated from WT mice. Twenty-four hours after stimulation, TNF- α and IL-6 levels were measured in culture supernatants using CBA (left panels). RNaseIII-treated poly(I:C) and PV5 were electrophoresed on a 2% agarose gel (right panels).

failed to induce TLR3-mediated IFN- β promoter activation by either extracellular stimulation in FCS-free medium or direct endosomal delivery using DOTAP (Fig. 7b,c). When PV5-D2 and -D4 were added to mouse splenic DCs or bone marrow-derived macrophages in the FCS-free conditions, IFN- β and proinflammatory cytokines, including TNF- α and IL-6, were produced in a TLR3-dependent manner, though their levels were relatively low compared with those induced by PV5-D1, D3 or D5 (Fig. 7d). These results suggest that longer stem structure with bulge and internal loops typically shown in PV5-D5 mfold model is the core RNA structure required for TLR3 activation in PV5 and also in PV6. In addition, shorter mismatched RNA duplexes such as PV5-D2 and -D4 can be

recognized by TLR3 with less activity in mouse DCs/macrophages if they hold the structure, which differs from TLR3 response in HEK293 cells. Given that RNA molecules have an appropriate tertiary interactions, the stability and TLR3-binding ability of these RNA molecules must be influenced by RNA tertiary structure.

Discussion

In the current study, we demonstrated, for the first time, that mouse/human TLR3 detects extracellular virus-derived RNA with stable stem structures to induce innate immune signalling. Functional PV-RNAs were degradation-resistant, and their ability




Figure 6 | Partial digestion of PV5 with MazF. (a) MazF-induced cleavage pattern of PV5 and the deletion mutants visualized on a denaturing 5% PAGE. PV5 was digested with MazF at room temperature, and other RNAs were digested at 37 °C. The cleavage pattern is schematically drawn at the bottom of the figure. MazF recognized ACA-cleavage sites are indicated by triangles. Black triangles indicate the observed cleavage sites and white triangles indicate sites not detected on the gel. Asterisks indicate the fragments produced by MazF-mediated ACA-specific digestion. Italic letters show the position numbers of the first A residues in ACA sequences of PV5. RNA size markers: DM192 (20-, 30-, 40- or 50-mer, Bio Dynamics Laboratory Inc.), PV5(216)(216-mer), PV5(244)(244-mer) and PV5(300)(300-mer). (b) Secondary structure of PV5 predicted by the mfold software. Rectangles show the ACA sites of PV5. The position numbers of the first A residues in ACA sequences of PV5 are shown. Solid arrows indicate the MazF-digestion sites. Broken arrow indicates the delayed digestion site.




Figure 7 | Mapping of TLR3-activating RNA structure in PV5. (a) Secondary structure of PV5-derived RNAs (PV5-D1–PV5-D5) predicted by the mfold software. (b) RNAs were incubated in FCS-free or -containing medium at 37°C. Non-treated RNA or RNA incubated for 30 min were loaded onto a 1% agarose gel. (c) TLR3-mediated IFN- β promoter activation induced by PV5 or PV5-derived RNAs in HEK293 cells transiently expressing TLR3. Cells were stimulated with indicated RNAs ($10 \mu\text{g ml}^{-1}$) (upper panel) or RNAs complexed with DOTAP ($1 \mu\text{g ml}^{-1}$) (lower panel). After 6 h, luciferase reporter activity was measured and expressed as the fold induction relative to the activity of unstimulated cells. Data are shown as the mean \pm s.d. Representative data from three independent experiments are shown. (d) Splenic CD11c $^{+}$ DCs (upper panels) or bone marrow-derived macrophages (lower panels) (2×10^6 per ml) isolated from TLR3 $^{-/-}$ or WT mice were stimulated with 100 pmol ml^{-1} PV5 or PV5-derived RNAs in FCS-free AIM medium. Twenty-four hours after stimulation, culture supernatants were collected, and IFN- β in the supernatants was quantified using ELISA. TNF- α and IL-6 levels were measured using CBA. Representative data from three independent experiments are shown (mean \pm s.d.).

to activate TLR3 was dependent on the dsRNA region within the RNA molecule, which is required for interaction with the N- and C-terminal dsRNA-binding sites of the TLR3 ECD. Based on the

structural analysis of the TLR3–dsRNA complex, it has been proposed that 40–50 bp dsRNA was the minimum signalling unit with two TLR3 molecules³¹. Jelinek *et al.*¹¹ reported that dsRNAs,

> 90 bp in length, triggered TLR3 oligomerization and efficiently induced IFN- β and TNF- α production in conventional murine DCs. Functional PV-RNAs, such as PV5 and PV6, induced TLR3-dependent IFN- α/β and proinflammatory cytokines from mouse CD11c⁺ DCs (Fig. 5); these RNAs appeared to oligomerize TLR3 molecules even though they harbour bulges and internal loops in their duplex structures. If this is the case, TLR3 recognizes not only perfect duplex of ~90 bp dsRNA but also the mismatched RNA duplex within ~600-nt PV-RNA. We identified the core RNA structure required for TLR3 activation in PV5, which is relatively long stem structure with bulge and internal loops typically shown in PV5-D5 mfold secondary structure. The fascinating model for TLR3 dimer formation has been proposed, in which shorter RNA duplexes of between 21 and 30 bp can form less stable complexes with two TLR3 molecules³². Thus, TLR3 appears to have flexibility to recognize RNA molecules.

Interestingly, PV5 segments (approximately 200 nts in length; PV5 a, b and c) lost the ability to activate TLR3 in HEK293 cells despite their degradation-resistant structure (Supplementary Fig. S3c), suggesting that an appropriate topology of multiple RNA duplexes are required for TLR3 activation. In addition, PV5-D2 and -D4 failed to activate IFN- β promoter in HEK293 cells expressing TLR3, but efficiently induced type I IFN and proinflammatory cytokine production from mouse splenic DCs and bone marrow-derived macrophages in a TLR3-dependent manner (Fig. 7). Recently, it has been reported that TLR3 undergoes cathepsin-mediated proteolytic processing, and both full-length and C-terminal cleaved form of TLR3 molecules reside in human retinal epithelial cell line and monocyte-derived DCs³⁸. It is interesting if shorter RNAs with mismatched duplex, such as PV5-D2 and -D4, are recognized by protease-processed TLR3 in mouse DCs or bone marrow-derived macrophages with different binding modes from intact TLR3³⁸. Indeed, the cleaved form of TLR3 is predominant in mouse macrophages³⁹, but less present in HEK293 cells⁴⁰, which may explain the different TLR3 responses to these RNAs between mouse DCs/macrophages and human HEK293 cells (Fig. 7).

There have been many reports indicating that TLR3-dependent inflammatory cytokine and chemokine production affects virus-induced pathology and host survival in RNA virus infections such as respiratory syncytial virus, influenza A virus and phlebovirus, a negative-strand RNA virus that produces minimal dsRNA as an intermediate product⁸. Furthermore, TLR3 functions as an endogenous sensor of necrosis and is required for chemokine production by peritoneal macrophages after co-culture with necrotic neutrophils²⁴. However, these biological studies have suffered from the lack of information about the actual molecules sensed by TLR3 in such infection/inflammatory states. More recently, Bernard *et al.*⁴¹ demonstrated that UV-damaged self-noncoding RNA is detected by TLR3. We suppose that viral/host RNAs with stable stem structures derived from infection- or inflammation-damaged cells activate TLR3 to induce cytokine and chemokine production.

In the case of PV infection, TLR3-mediated type I IFN production is important for viral clearance *in vivo*^{15,16}. *In vitro* PV infection of splenic DCs promotes type I IFN production in a TLR3-dependent manner. The positive-stranded ssRNAs and the replicative form are robustly present in PV-infected cells, which might be segmented into functional ssRNAs similar to PV5 and PV6 extracellularly due to necrosis. Hence, in the local environment, segmented virus-derived structured RNAs can function as a TLR3 ligand. The flexible RNA-recognition mode of TLR3 may have some advantage to protect host against wide spectrum of virus infection.

Notably, RNA uptake is required for TLR3 signalling. Functional PV-RNAs possess the essential structural elements required for both cellular uptake and TLR3 oligomerization. We found that raftlin, a cytoplasmic lipid raft protein, is a molecule that participates in uptake of PV-RNAs and delivery to TLR3-positive early endosomes (Fig. 4). The features of the TLR3-recognizing PV-RNAs are consistent with our previous results that raftlin mediates poly(I:C) cellular uptake through interaction with the clathrin-AP-2 complex in human myeloid DCs and epithelial cells³⁵. In addition, uptake of B/C-type CpG ODNs that share their uptake receptor with poly(I:C) was also mediated by raftlin^{33,35}. Given that PV5-induced TLR3 activation in HEK293 cells was inhibited by pre-treatment with the B-type CpG ODN (Supplementary Fig. S5), PV5 likely utilizes the poly(I:C)/ODN-uptake receptor for endocytosis. Although CD14 and the scavenger receptor class A were reported to act as a poly(I:C)-uptake receptor in mouse macrophages and human bronchial epithelial cells, respectively^{42,43}, they did not participate in poly(I:C)/ODN cellular uptake in human DCs because of their absence on the cell surface¹². There must be an additional uptake receptor for poly(I:C)/ODN. Identification of the uptake receptor for virus RNAs is important for improving our understanding of the innate immune response to viral infection and sterile inflammation.

TLRs recognize pathogen- or damage-associated molecular patterns and promote the activation of the innate and adaptive immune responses through ligand-induced oligomerization^{44,45}. Structural analyses of TLR3, TLR4, TLR5, TLR2/1 and TLR2/6 ECDs, and their complexes with typical ligands, demonstrated that each TLR possessed ligand-binding sites or pockets and a dimerizing interface, which allowed for ligand-induced receptor dimerization^{46,47}. Although there are multiple ligands for each TLR, it remains unknown whether they share common structural features. The current study is the first to characterize the RNA structure capable of triggering TLR3 activation and demonstrate that viral RNAs with intermittent stem structure are recognized by an uptake receptor and by TLR3, inducing innate immune signalling. Precise analyses of the mechanisms underlying pattern recognition by TLRs using different ligands might be important for engineering synthetic TLR-activating ligands.

Methods

Cell culture and reagents. HEK293 and Vero cells were maintained in DMEM (Invitrogen) supplemented with 10% heat-inactivated FCS (Invitrogen) and antibiotics. HeLa cells were kindly provided by Dr T. Fujita (Kyoto University) and maintained in Eagle's minimal essential medium (Nissui, Tokyo, Japan) supplemented with 1% l-glutamine and 5% heat-inactivated FCS. Normal embryonic lung fibroblasts, MRC5 cells, were maintained in MEM-alpha (Invitrogen) supplemented with 10% heat-inactivated FCS and antibiotics. The anti-human TLR3 monoclonal antibody (mAb) (clone TLR3.7) was generated in our laboratory⁷. The anti-human raftlin polyclonal Ab (pAb) and anti-mouse TLR3 mAb were kindly provided by Dr K. Saeki (Kyushu University) and Dr D. M. Segal (National Institutes of Health, MD), respectively.^{34,11} Anti-EEA1 pAb (PA1-063) was purchased from Affinity Bioreagents; anti- β -actin mAb (A2228) was purchased from Sigma; the anti-LAMP1 mAb (328601) was purchased from Biologend; the anti-TICAM-1 pAb (4596) was purchased from Cell Signaling; and Alexa Fluor-488 and -633-conjugated secondary antibodies were purchased from Invitrogen. Poly(I:C) was purchased from Amersham Biosciences. RNase A and RNase III were purchased from Ambion.

Mice. Inbred C57BL/6 WT mice were purchased from CLEA Japan (Tokyo, Japan). TLR3^{-/-} mice were provided by Dr S. Akira (Osaka University). Mice were maintained under specific pathogen-free conditions in the animal facility of the Hokkaido University Graduate School of Medicine. Female mice of 6–10 week of age were used in all experiments that were performed according to the guidelines established by the Hokkaido University Animal Care and Use Committee.

Plasmids. The cDNA fragments encoding the open-reading frame of human TLR3 was amplified using RT-PCR with total RNA prepared from monocyte-derived DCs and was ligated into the cloning site of the expression vector, pEF-BOS, which was a gift from Dr S. Nagata (Kyoto University)⁴⁸. Mahoney PV complementary

DNA was provided by Dr S. Koike (Tokyo Metropolitan Institute of Medical Science, Tokyo). TLR3-mutant plasmids were gifts from Dr K. Fukuda (Yamagata University)²⁹.

RNA extraction from PV-infected cells. Vero cells were infected with PV or not infected. Forty-eight hours later, cells and culture supernatants were divided by centrifugation (2,000 r.p.m., 10 min). TRIzol reagent (Invivogen) was added to cell pellets for extraction of RNA. Obtained RNAs were purified by ethanol precipitation, and concentration was determined by measuring the absorbance at 260 nm in a spectrophotometer.

Preparation of RNA. DNA fragments containing the PV gene segment and the T7 promoter sequence were amplified using PCR with specific primers and the PV-cDNA as a template (Supplementary Table S2). The PV sense and antisense RNAs from the PCR products were transcribed *in vitro* using an AmpliScribe T7 transcription kit (Epicentre Technologies, Madison, WI, USA) according to the manufacturer's protocol. The transcribed products were separated on a 1% agarose gel, and the band corresponding to PV RNA was excised using RECOCHIP (Takara). Then, eluted RNAs were ethanol precipitated and resuspended in RNase-free water. To generate dsRNA, sense and antisense RNAs were annealed. PV-ss/dsRNAs were pre-treated with polymyxin B (5 µg ml⁻¹) for 1 h before being added to mouse macrophages and DCs. RNA was labelled with Cy3 maleimide mono-reactive dye (GE Healthcare) using the 5' EndTag Nucleic Acid Labeling System (Vector Laboratories, Inc.). Cy3-PV5 showed a full activity.

Reporter gene assay. HEK293 cells (8 × 10⁵ cells per well) were cultured in six-well plates and transfected with the TLR3-expression vector or an empty vector (400 ng per well), together with the reporter plasmid (400 ng per well) and an internal control vector pRL-TK (Promega, Madison, WI, USA) (20 ng per well) using FuGENE HD (Roche). The p-125 luc reporter containing the human IFN-β promoter region (-125 to +19) was provided by Dr T. Taniguchi (University of Tokyo). After 24 h, cells were collected and resuspended with FCS-free or -containing medium. Then, cells were seeded on 96-well plates and stimulated with the indicated RNAs. Six hours later, cells were lysed using the passive lysis buffer (Promega), and Firefly and *Renilla* luciferase activities were determined using a dual-luciferase reporter assay kit (Promega). The Firefly luciferase activity was normalized by *Renilla* luciferase activity and was expressed as the fold stimulation relative to activity in non-stimulated cells.

Filter binding assay. Radioisotope labelling of PV-RNAs by *in vitro* transcription with [³²P-ATP] was carried out as previously described⁴⁹. Labelled PV-RNAs (2 nM) were mixed with varying concentrations (none or 6.25, 12.5, 25, 50, 100 or 200 nM) of human TLR3 (amino acid 27–711; R&D Systems) and adjusted to a total volume of 25 µl using binding buffer (pH 5.0–7.0) containing 100 mM NaCl (20 mM AcONa (pH 5.0–6.0) or 20 mM Tris-HCl (pH 6.5–7.0)). After 30 min incubation, the mixtures were passed through a nitrocellulose filter and washed twice with 500 µl reaction buffer. The amount of bound RNA was measured using BAS 2500 (Fujifilm), and binding activities were calculated as the percentage of input RNA.

Quantitative PCR. Total RNA was extracted using the RNeasy mini kit (Qiagen, Valencia, CA) and reverse transcribed using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems) and random primers according to the manufacturer's instructions. qPCR was performed using the indicated primers (Supplementary Table S3) and the Step One Real-time PCR system (Applied Biosystems).

RNA interference and immunoblotting. siRNA duplexes (Raftlin, catalogue number s23219; negative control, catalogue number AM4635) were purchased from Ambion-Applied Biosystems. siRNA for TICAM-1 was purchased from Xeragon Inc. (Birmingham, AL, USA). HEK293 cells were cultured in 24-well plates and transfected with 20 pmol each siRNA, together with the expression vector for human TLR3 (200 ng), IFN-β promoter plasmid (100 ng) and an internal control vector (1.5 ng) using Lipofectamine 2000. Forty-eight hours after transfection, cells were stimulated with 10 µg ml⁻¹ ligands for 6 h. Cells were lysed and dual-luciferase activities were measured according to the manufacturer's instructions (Promega). Cell lysates were clarified by centrifugation and mixed with denaturing buffer. Samples were analysed using 10% SDS-PAGE followed by immunoblotting with anti-raftlin pAb (1/1,000), anti-β-actin mAb (1/1,000) or anti-TICAM-1 pAb (1/500). In the case of HeLa cells, cells cultured in 12-well plates were transfected with 40 pmol each siRNA using Lipofectamine 2000.

Confocal microscopy. HeLa cells (1.0 × 10⁵ cells per well) were plated onto micro-cover glasses (Matsunami, Tokyo, Japan) in a 12-well plate. The following day, cells were incubated with 15 µg ml⁻¹ Cy3-labelled PV5 for 30 min at 4 °C. Cells were washed twice and further incubated for 5–60 min at 37 °C. At timed intervals, cells

were fixed with 4% paraformaldehyde for 15 min and permeabilized using PBS containing 0.2% Triton and 1% BSA for 15 min. Fixed cells were labelled with anti-EEA1 pAb (1/200), anti-LAMP1 mAb (1/300) or anti-human TLR3 mAb (1/500) overnight at 4 °C. Then, Alexa Fluor-488- or -633-conjugated secondary Abs (1/400) were used to visualize the primary Abs. Prolong Gold was used for staining the nuclei. Cells were visualized at a ×63 magnification using an LSM510 META microscope (Zeiss, Jena, Germany).

Purification of mouse DCs from spleen. Splenocytes from WT or TLR3^{-/-} mice were treated with 400 IU MandleU per ml collagenase D (Roche) at 37 °C for 25 min in HBSS (Sigma-Aldrich). EDTA was added to the cell suspensions and incubated for an additional 5 min at 37 °C. After lysis of red blood cells using the ACK lysis buffer, splenocytes were incubated with magnetic-activated cell sorting anti-CD11c-conjugated microbeads, and DCs were purified using magnetic separation columns as indicated by the manufacturer (Miltenyi Biotec, Auburn, CA, USA). Positively selected cells were isolated and suspended in RPMI 1640 (Invitrogen) supplemented with 10% heat-inactivated FCS and antibiotics. For isolation of CD8α⁺ DCs, the magnetic-activated cell sorting CD8α⁺ DC-positive selection kit was used according to the manufacturer's instructions. Purity was checked routinely by FACS and was found to be >80% (CD11c⁺) or >90% (CD8α⁺), respectively.

Enzyme-linked immunosorbent assay and cytometric bead array. Cells were stimulated with the indicated RNAs in FCS-containing medium or FCS-free AIM-V medium (Invitrogen). Twenty-four hours after stimulation, culture supernatants were collected and analysed for cytokine levels with enzyme-linked immunosorbent assay (ELISA) or cytometric bead array (CBA). ELISA kits for IFN-α and IFN-β were purchased from PBL Biomedical Laboratories and were performed according to the manufacturer's instructions. CBA flex sets for mouse IL-6 and TNF-α were purchased from BD Bioscience. Experiments were performed according to the manufacturer's instructions, and samples were analysed using the FACS Aria (BD Bioscience).

Statistical analysis. Statistical significance of differences between groups was determined by the Student's *t*-test.

Prediction of RNA secondary structure. The secondary structure of RNAs was modelled using mfold (<http://mfold.rna.albany.edu/?q=mfold>), RNAfold (<http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi>) and centroidfold program (<http://www.ncrna.org/software/centroidfold/>).

References

- Stetson, D. B. & Medzhitov, R. Type I interferons in host defense. *Immunity* **25**, 373–381 (2006).
- Vilcek, J. Fifty years of interferon research: aiming at a moving target. *Immunity* **25**, 343–348 (2006).
- Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. *Cell* **124**, 783–801 (2006).
- Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Recognition of double stranded RNA and activation of NF-κB by Toll-like receptor 3. *Nature* **413**, 732–738 (2001).
- Matsumoto, M., Kikkawa, S., Kohase, M., Miyake, K. & Seya, T. Establishment of monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. *Biochem. Biophys. Res. Commun.* **293**, 1364–1369 (2002).
- Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T. & Seya, T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-β induction. *Nat. Immunol.* **4**, 161–167 (2003).
- Yamamoto, M. *et al.* Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. *Science* **301**, 640–643 (2003).
- Weber, F., Wagner, V., Rasmussen, S. B., Hartmann, R. & Paludan, S. R. Double-stranded RNA is produced by positive-stranded RNA viruses and DNA viruses but not in detectable amounts by negative-stranded RNA viruses. *J. Virol.* **80**, 5059–5064 (2006).
- Matsumoto, M. *et al.* Subcellular localization of Toll-like receptor 3 in human dendritic cells. *J. Immunol.* **171**, 3154–3162 (2003).
- Jongbloed, S. L. *et al.* Human CD141⁺ (BDCA-3)⁺ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. *J. Exp. Med.* **207**, 1247–1260 (2010).
- Jelinek, I. *et al.* TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. *J. Immunol.* **186**, 2422–2429 (2011).
- Matsumoto, M. & Seya, T. TLR3: Interferon induction by double-stranded RNA including poly(I:C). *Adv. Drug. Deliv. Rev.* **60**, 805–812 (2008).
- Hardarson, H. S. *et al.* Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injury. *Am. J. Physiol. Heart Circ. Physiol.* **292**, 251–258 (2007).

14. Negishi, H. *et al.* A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. *Proc. Natl Acad. Sci. USA* **105**, 20446–20451 (2008).
15. Oshiumi, H. *et al.* The TLR3-TICAM-1 pathway is mandatory for innate immune responses to poliovirus infection. *J. Immunol.* **187**, 5320–5327 (2011).
16. Abe, Y. *et al.* The Toll-like receptor 3-mediated antiviral response is important for protection against poliovirus infection in poliovirus receptor transgenic mice. *J. Virol.* **86**, 185–194 (2012).
17. Zhang, S.-Y. *et al.* TLR3 deficiency in patients with herpes simplex encephalitis. *Science* **317**, 1522–1527 (2007).
18. Guo, Y. *et al.* Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. *J. Exp. Med.* **208**, 2083–2098 (2011).
19. Sancho-Shimizu, V. *et al.* Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. *J. Clin. Invest.* **121**, 4889–4902 (2011).
20. Wang, T. *et al.* Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. *Nat. Med.* **10**, 1366–1373 (2004).
21. Goffic, R. L. *et al.* Detrimental contribution of the Toll-like receptor (TLR) 3 to influenza A virus-induced acute pneumonia. *PLoS Pathog.* **2**, 526–535 (2006).
22. Gowen, B. B. *et al.* TLR3 deletion limits mortality and disease severity due to phlebovirus infection. *J. Immunol.* **177**, 6301–6307 (2006).
23. Karikó, K., Ni, H., Capodici, J., Lamphier, M. & Weissman, D. mRNA is an endogenous ligand for Toll-like receptor 3. *J. Biol. Chem.* **279**, 12542–12550 (2004).
24. Cavassani, K. A. *et al.* TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. *J. Exp. Med.* **205**, 2609–2621 (2008).
25. Kato, H. *et al.* Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* **441**, 101–105 (2006).
26. Racaniello, V. R. Picornaviridae: the viruses and their replication. In *Section II: Specific Virus Families: Fields Virology* 5th edn (eds Knipe, D. M. & Howley, P. M.) 795–838 (Lippincott Williams & Wilkins, 2007).
27. Leonard, J. N. *et al.* The TLR3 signaling complex forms by cooperative receptor dimerization. *Proc. Natl Acad. Sci. USA* **105**, 258–263 (2008).
28. Hofacker, I. *et al.* Fast folding and comparison of RNA secondary structures. *Monatsh. Chem.* **125**, 167–188 (1994).
29. Fukuda, K. *et al.* Modulation of double-stranded RNA recognition by the N-terminal histidine-rich region of the human Toll-like receptor 3. *J. Biol. Chem.* **283**, 22787–22794 (2008).
30. Bell, J. K. *et al.* Leucine-rich repeats and pathogen recognition in Toll-like receptors. *Trends Immunol.* **24**, 528–533 (2003).
31. Liu, L. *et al.* Structural basis of Toll-like receptor 3 signaling with double-stranded RNA. *Science* **320**, 379–381 (2008).
32. Pirher, N., Ivicak, K., Pohar, J., Bencina, M. & Jerala, R. A second binding site for double-stranded RNA in TLR3 and consequences for interferon activation. *Nat. Struct. Mol. Biol.* **15**, 761–763 (2008).
33. Itoh, K., Watanabe, A., Funami, K., Seya, T. & Matsumoto, M. The clathrin-mediated endocytic pathway participates in dsRNA-induced IFN- β production. *J. Immunol.* **181**, 5522–5529 (2008).
34. Saeki, K., Miura, Y., Aki, D., Kurosaki, T. & Yoshimura, A. The B cell-specific major raft protein, Raftlin, is necessary for the integrity of lipid raft and BCR signal transduction. *EMBO J.* **22**, 3015–3026 (2003).
35. Watanabe, A. *et al.* Raftlin is involved in the nucleocapture complex to induce poly(I:C)-mediated TLR3 activation. *J. Biol. Chem.* **286**, 10702–10711 (2011).
36. Zhang, Y. *et al.* MazF cleaves cellular mRNAs specifically at ACA to block protein synthesis in *Escherichia coli*. *Mol. Cell* **12**, 913–923 (2003).
37. Yamaguchi, Y. & Inouye, M. mRNA interferases, sequence-specific endoribonucleases from the toxin-antitoxin systems. *Prog. Mol. Biol. Transl. Sci.* **85**, 467–500 (2009).
38. Garcia-Cattaneo, A. *et al.* Cleavage of Toll-like receptor 3 by cathepsins B and H is essential for signaling. *Proc. Natl Acad. Sci. USA* **109**, 9053–9058 (2012).
39. Ewald, S. E. *et al.* Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. *J. Exp. Med.* **208**, 643–651 (2011).
40. Toscano, F. *et al.* Cleaved/associated TLR3 represents the primary form of the signaling receptor. *J. Immunol.* **190**, 764–773 (2013).
41. Bernard, J. J. *et al.* Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. *Nat. Med.* **18**, 1286–1291 (2012).
42. Lee, H. K. S., Dunzendorfer, K., Soldau, K. & Tobias, P. S. Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. *Immunity* **24**, 153–163 (2006).
43. Limmon, G. V. *et al.* Scavenger receptor class-A is a novel cell surface receptor for double-stranded RNA. *FASEB J.* **22**, 159–167 (2008).
44. Medzhitov, R. & Janeway, Jr C. A. Innate immunity: the virtues of a nonclonal system of recognition. *Cell* **91**, 295–298 (1997).
45. Kono, H. & Rock, K. L. How dying cells alert the immune system to danger. *Nat. Rev. Immunol.* **8**, 279–289 (2008).
46. Kang, J. Y. & Lee, J.-O. Structural biology of the Toll-like receptor family. *Annu. Rev. Biochem.* **80**, 917–941 (2011).
47. Yoon, S. I. *et al.* Structural basis of TLR5-flagellin recognition and signaling. *Science* **335**, 859–864 (2012).
48. Mizushima, S. & Nagata, S. pEF-BOS, a powerful mammalian expression vector. *Nucleic Acid Res.* **18**, 5322–5323 (1990).
49. Fukuda, K. *et al.* Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease. *Eur. J. Biochem.* **267**, 3685–3694 (2000).

Acknowledgements

We are grateful to our laboratory members for their invaluable discussions. We also thank Dr S. Akira (Osaka University) for providing TLR3^{-/-} mice, Dr S. Koike (Tokyo Metropolitan Institute of Medical Science) for PV-cDNA, Dr D. M. Segal (National Institutes of Health) for anti-mouse TLR3 mAb, Dr K. Saeki (Kyushu University) for anti-raftlin antibody, Dr T. Taniguchi (University of Tokyo) for p-125 luc reporter plasmid, Dr S. Nagata (Kyoto University) for pEF-BOS expression vector and Dr K. Fukuda (Yamagata University) for TLR3-mutant plasmids. This work was supported in part by Grants-in-Aid from the Ministry of Education, Science, and Culture, the Ministry of Health, Labor, and Welfare of Japan, and by the Akiyama Life Science Foundation.

Author contributions

M.T. and M.M. conceived and designed the experiments. M.T. and F.N. performed the experiments. M.T., F.N., T.S. and M.M. analysed the data. M.T. and M.M. wrote the paper.

Additional information

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Tatematsu, M. *et al.* Toll-like receptor 3 recognizes incomplete stem structures in single-stranded viral RNA. *Nat. Commun.* **4**:1833 doi: 10.1038/ncomms2857 (2013).

EXPERT OPINION

1. Introduction
2. TLR3: distribution and localization
3. TLR3: structure and function
4. Therapeutic TLR3 agonists
5. Specific ligands for TLR3 without activation of the MAVS pathway
6. Other RNA derivatives in tumor environment
7. Cellular immunity induced in tumor microenvironment
8. Expert opinion

Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer

Tsukasa Seya[†], Masahiro Azuma & Misako Matsumoto

Hokkaido University, Graduate School of Medicine, Department of Microbiology and Immunology, Sapporo, Japan

Introduction: Many forms of RNA duplexes with agonistic activity for pattern-recognition receptors have been reported, some of which are candidates for adjuvant immunotherapy for cancer. These RNA duplexes induce cytokines, interferons (IFNs) and cellular effectors mainly via two distinct pathways, TLR3/TICAM-1 and MDA5/MAVS.

Areas covered: We determined which pathway of innate immunity predominantly participates in evoking tumor immunity in response to RNA adjuvants.

Expert opinion: In knockout (KO) mouse studies, robust cytokine or IFN production is dependent on systemic activation of the MAVS pathway, whereas maturation of dendritic cells (DCs) to drive cellular effectors (i.e., NK and CTL) depends on the TICAM-1 pathway in DCs. MAVS activation often causes endotoxin-like cytokinemia, while the TICAM-1 activation does not. Unlike the TLR/MyD88 pathway, this TICAM-1 pathway barely accelerates tumor progression. Although the therapeutic effect in human patients of MAVS-activating or TICAM-1-activating RNA duplexes remains undetermined, the design of a TLR3 agonist with optimized toxicity and dose is an important goal for human immunotherapy. Here we summarize current knowledge on available RNA duplex formulations, and offer a possible approach to developing a promising RNA duplex for clinical tests.

Keywords: double-stranded RNA, MAVS (IPS-1, Cardif, VISA), immunotherapy, TICAM-1 (TRIF), TLR3

Expert Opin. Ther. Targets [Early Online]

1. Introduction

Toll-like receptor 3 (TLR3) was first identified in 2001 as a membrane-associated dsRNA sensor in TLR3^{-/-} mice in which polyI:C-mediated NF- κ B activation was severely hampered [1]. While it was suggested that signaling via TLR3, like TLR4, induced type I IFN [2], no conclusive data as to how this was achieved by dsRNA recognition were offered in that report [1]. We have established a mAb, TLR3.7, against human TLR3, that blocks dsRNA (polyI:C)-mediated type I IFN production in the human fibroblast line MRC5, and that demonstrates TLR3 localization on the cell surface membrane of these fibroblasts [3]. Moreover, immunoprecipitation analysis demonstrated that polyI:C-stimulated TLR3 formed a molecular complex with cytoplasmic proteins [3]. Ultimately, TICAM-1 (TRIF) was identified as the TLR3 adaptor [4]. By demonstrating that TLR3 recognizes dsRNA on the cell membrane and delivers an intracellular signal for the induction of type I IFN, these reports collectively link TLR3 to the type I IFN production pathways in fibroblasts in both human and mouse (Figure 1A).

RIG-I and MDA5 were soon discovered as cytoplasmic sensors for dsRNA that induced type I IFN [5,6]. It is reasonable that virus dsRNA replicating in cytoplasm is recognized by RIG-I/MDA5 of infected cells. What is the role of the

informa
healthcare

Article highlights.

- dsRNA or polyI:C induces cytokines/IFNs through recognition by RNA sensors, TLR3 or RIG-I/MDA5.
- The cytoplasmic sensors RIG-I/MDA5 cause systemic cytokinemia in response to *in vivo* administration of polyI:C while the endosomal dsRNA sensor TLR3 does not.
- The TLR3 pathway resides in myeloid cells and mainly involved in DC-driven effector cells induction.
- TLR3-specific dsRNA stimulation with no involvement of RIG-I/MDA5 generates antitumor adjuvant activity without robust cytokine induction.
- TLR/MyD88 is a main pathway for NF- κ B activation, which harbors protumor activity; yet, the TLR3 pathway does not involve MyD88 activation.
- Although polyI:C is too toxic to culminate driving cellular immunity against cancer, developing nontoxic antitumor adjuvants from derivatives of dsRNA would be feasible by redesigning dsRNA.

This box summarizes key points contained in the article.

TLR3 pathway for IFN induction in viral infection should have been reconsidered. PolyI:C has been historically used as an IFN inducer, and has been shown to engage both TLR3 and MDA5 [7,8]. Gene disruption studies in mice suggest that serum IFN levels in polyI:C-injected mice are increased primarily by the RIG-I/MDA5 pathway [7]. TLR3 is involved in local secretion of type I IFN limitedly in nearby tissues and organs (Figure 1B). Current understanding of this issue is that the fundamental function of TLR3 is not to induce robust IFNs/cytokines to alarm infection over whole body but to evoke cellular immunity, as mentioned below.

An alternative function of the TLR3 pathway has been clarified through studies of dsRNA (polyI:C)-stimulated or virus-infected tumor cells (Figure 1A). Cell death or growth is promoted in response to dsRNA, since TLR3 links to the RIP1 pathway to induce NF- κ B activation and RIP1/RIP3-mediated cytolysis in tumor cells [9,10]. In addition, tumor-associated macrophages (M ϕ) (TAM) switches from a tumor-supporting to a tumoricidal phenotype in response to dsRNA [11]. Hence, the physiological role of the TLR3 pathway in tumor cells appears to provide dead cell-derived tumor Ag to DC and promote tumor immunity. Ultimately, these results suggest that if Ag and TLR3 agonist are provided for DC maturation, tumor cells expressing the Ag will be targeted by effector cells induced via the DC-derived immune response (Figure 2). Here, we focus on the role of dsRNA in evoking cellular immunity for cancer.

2. TLR3: distribution and localization

The gene encoding TLR3 is evolutionarily conserved across humans, mice, chickens and teleost fish [12-14] and TLR3 in all these species induces IFN production in response to

polyI:C [13], implicating TLR3 as a potential viral dsRNA sensor in vertebrates [14]. However, viruses usually replicate in cytoplasm where no TLR3 is distributed. Furthermore, cell types expressing TLR3 are limited, at least in humans and mice, therefore TLR3 is unlikely to systemically protect tissues or organs from virus infection.

A human mAb against TLR3, TLR3.7, blocks dsRNA (polyI:C)-mediated type I IFN production in the human fibroblast lines where TLR3 localized on the cell surface membrane [4]. In contrast, the TLR3.7 mAb does not block the production of IFN by TLR3 in human monocyte-derived dendritic cells (MoDC) [15]. Electron or confocal microscopic analysis in these cells suggested that TLR3 is localized to endosomal compartment [15,16], which were later identified as early endosomes. Hence, human TLR3 is localized in a cell type-specific fashion, such that epithelial cells and fibroblasts, including MRC5 cells, express TLR3 on the cell surface, while in myeloid cells, TLR3 localizes to the endosome (Figure 1A). The surface-expressed type of TLR3 is positioned next to sample dsRNA in the extracellular milieu to transmit IFN-inducing signaling, whereas endosomal TLR3 engages phagocytosed dsRNA for signaling. Both types of endogenous TLR3 could be detected by TLR3.7 mAb by imaging analysis [15].

Since myeloid cells, including DC and M ϕ , take up external dsRNA into the endosome via phagocytosis [15-17], our current hypothesis is that endosomal TLR3 plays a role in sampling viral materials for augmenting antigen (Ag) presentation (Figure 1B). This model is gaining approval as the authentic adjuvant function of TLR3.

Human endosomal TLR3 is primarily expressed by myeloid cells, including dendritic cells (DCs) (Table 1) [18]. There are many subsets of DCs in humans, of which human CD141 (BDCA3)⁺ DCs express high levels of TLR3 [19]. Human epithelial and endothelial cells express detectable amounts of TLR3 on their cell surfaces [3,20,21]. In contrast, tumor cells and malignantly transformed cells express TLR3 in endosomes rather than on their cell surfaces [18]. Tumor cells, therefore, unlike normal epithelial and endothelial cells, cannot directly sample environmental RNAs.

3. TLR3: structure and function

TLR3 is a type I membrane protein consisting of extracellular leucine-rich repeats and a cytoplasmic Toll-IL-1 receptor homology domain (TIR). The acidic environment in the endosomal lumen allows TLR3 to more tightly bind dsRNA than neutral cell-surface irrespective of the sequence. Forty to fifty base pairs of non-mismatched dsRNA interacts with homodimeric TLR3 almost exclusively with the sugar phosphate backbone rather than through the base moieties [22-24]. Intriguingly, the interaction of dsRNA with TLR3 does not trigger conformational changes, but rather facilitates homodimerization, which brings the intracellular TIRs of TLR3s in close proximity of each other [23]. TLR3 homodimerization recruits the adaptor TICAM-1 (TRIF) to the TIR domains [3],